Changes in Diabetes-Related Complications in the United States, 1990–2010

correction a group of patients with intermediate-risk disease (hazard ratio for death with pazopanib, 0.90; 95% CI, 0.74 to 1.09), and the median overall survival was 9.9 months among 67 patients who received pazopanib (95% CI, 7.3 to 12.3) and 7.7 months among 52 patients who received sunitinib (95% CI, 5.4 to 11.9) in a group of patients with poorrisk disease (hazard ratio for death with pazopanib, 0.85; 95% CI, 0.56 to 1.28).Thirty-four patients who received pazopanib (6%) and 23 patients who received sunitinib (4%) continued on-study treatment.The median ontreatment period was 8.1 months for pazopanib and 7.6 months for sunitinib.The two most common reasons for treatment discontinuation were disease progression (in 311 of 554 patients who received pazopanib 56% and in 329 of 548 patients who received sunitinib 60%) and adverse events (in 132 of 554 patients who received pazopanib 24% and 107 of 548 patients who received sunitinib 20%).Safety results were consistent with those reported in our article. 1Post-study antiangiogenesis agents or inhibitors of the mammalian target of rapamycin were administered in 306 patients who received pazopanib (55%) and in 299 patients who received sunitinib (54%).In summary, similar overall survival outcomes support the findings of the primary analysis of progression-free survival, which showed the noninferiority of pazopanib versus sunitinib as firstline treatment for clear-cell renal-cell carcinoma.